316 related articles for article (PubMed ID: 27390104)
21. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
[TBL] [Abstract][Full Text] [Related]
22. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.
Patil VV; Guzman M; Carter AN; Rathore G; Yoshor D; Curry D; Wilfong A; Agadi S; Swann JW; Adesina AM; Bhattacharjee MB; Anderson AE
Neuropathology; 2016 Apr; 36(2):146-56. PubMed ID: 26381727
[TBL] [Abstract][Full Text] [Related]
23. Subependymal giant cell astrocytoma--a clinicopathological study of 23 cases with special emphasis on histogenesis.
Sharma MC; Ralte AM; Gaekwad S; Santosh V; Shankar SK; Sarkar C
Pathol Oncol Res; 2004; 10(4):219-24. PubMed ID: 15619643
[TBL] [Abstract][Full Text] [Related]
24. Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.
Zordan P; Cominelli M; Cascino F; Tratta E; Poliani PL; Galli R
J Clin Invest; 2018 Apr; 128(4):1688-1706. PubMed ID: 29389670
[TBL] [Abstract][Full Text] [Related]
25. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
26. mTOR cascade activation distinguishes tubers from focal cortical dysplasia.
Baybis M; Yu J; Lee A; Golden JA; Weiner H; McKhann G; Aronica E; Crino PB
Ann Neurol; 2004 Oct; 56(4):478-87. PubMed ID: 15455405
[TBL] [Abstract][Full Text] [Related]
27. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
Appalla D; Depalma A; Calderwood S
Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
[TBL] [Abstract][Full Text] [Related]
28. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
29. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.
Malik AR; Liszewska E; Skalecka A; Urbanska M; Iyer AM; Swiech LJ; Perycz M; Parobczak K; Pietruszka P; Zarebska MM; Macias M; Kotulska K; Borkowska J; Grajkowska W; Tyburczy ME; Jozwiak S; Kwiatkowski DJ; Aronica E; Jaworski J
Acta Neuropathol Commun; 2015 Jul; 3():48. PubMed ID: 26220190
[TBL] [Abstract][Full Text] [Related]
30. Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex.
Ess KC; Kamp CA; Tu BP; Gutmann DH
Neurology; 2005 Apr; 64(8):1446-9. PubMed ID: 15851742
[TBL] [Abstract][Full Text] [Related]
31. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
32. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
[TBL] [Abstract][Full Text] [Related]
33. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
Jiang T; Du J; Raynald ; Wang J; Li C
World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma.
You H; Kim YI; Im SY; Suh-Kim H; Paek SH; Park SH; Kim DG; Jung HW
J Neurooncol; 2005 Aug; 74(1):1-8. PubMed ID: 16078101
[TBL] [Abstract][Full Text] [Related]
35. Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report.
Beaumont TL; Godzik J; Dahiya S; Smyth MD
J Neurosurg Pediatr; 2015 Aug; 16(2):134-7. PubMed ID: 25978531
[TBL] [Abstract][Full Text] [Related]
36. CD44 expression in tuberous sclerosis.
Arai Y; Takashima S; Becker LE
Pathobiology; 2000; 68(2):87-92. PubMed ID: 10878505
[TBL] [Abstract][Full Text] [Related]
37. Impaired oligodendroglial turnover is associated with myelin pathology in focal cortical dysplasia and tuberous sclerosis complex.
Scholl T; Mühlebner A; Ricken G; Gruber V; Fabing A; Samueli S; Gröppel G; Dorfer C; Czech T; Hainfellner JA; Prabowo AS; Reinten RJ; Hoogendijk L; Anink JJ; Aronica E; Feucht M
Brain Pathol; 2017 Nov; 27(6):770-780. PubMed ID: 27750396
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex.
Sun FJ; Zhang CQ; Chen X; Wei YJ; Li S; Liu SY; Zang ZL; He JJ; Guo W; Yang H
J Neuroinflammation; 2016 Apr; 13(1):85. PubMed ID: 27095555
[TBL] [Abstract][Full Text] [Related]
39. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.
Giannikou K; Zhu Z; Kim J; Winden KD; Tyburczy ME; Marron D; Parker JS; Hebert Z; Bongaarts A; Taing L; Long HW; Pisano WV; Alexandrescu S; Godlewski B; Nellist M; Kotulska K; Jozwiak S; Roszkowski M; Mandera M; Thiele EA; Lidov H; Getz G; Devinsky O; Lawrence MS; Ligon KL; Ellison DW; Sahin M; Aronica E; Meredith DM; Kwiatkowski DJ
Mod Pathol; 2021 Feb; 34(2):264-279. PubMed ID: 33051600
[TBL] [Abstract][Full Text] [Related]
40. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
